All In Biotech

Drug Trial Radar · NCT06671509

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment

A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics and Safety of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment

Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Mar 22, 2024

Primary completion

Apr 18, 2024

Study completion Aug 7, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objectives: To evaluate the effect of the subjects with mild (Child Pugh A), moderate (Child Pugh B) and normal hepatic impairment on the pharmacokinetics of YZJ-1139 Secondary Objectives: To evaluate the safety of a single oral dose of YZJ-1139 in subjects with mild, moderate and normal hepatic impairment

Conditions

  • Insomnia
  • Hepatic Impairment

Interventions

  • YZJ-1139Drug

    Single oral dose, 20 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of YZJ-1139Time frame: From Day 1 to Day 3
  2. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of YZJ-1139Time frame: From Day 1 to Day 3
  3. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUClast) of YZJ-1139Time frame: From Day 1 to Day 3
  4. Time of Maximum Observed Plasma Concentration (Tmax) of EntrectinibTime frame: From Day 1 to Day 3
  5. Apparent Terminal Elimination Half-life (t1/2) of EntrectinibTime frame: From Day 1 to Day 3
  6. Apparent Oral Clearance (CL/F) of EntrectinibTime frame: From Day 1 to Day 3
  7. The Apparent Volume of Distribution (Vz/F) of EntrectinibTime frame: From Day 1 to Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.